Breaking News Instant updates and real-time market news.

TAK

Takeda Pharmaceutical

$17.88

-0.6 (-3.25%)

, BCRX

BioCryst

$7.89

0.19 (2.47%)

12:25
04/18/19
04/18
12:25
04/18/19
12:25

Piper Jaffray biotech analysts to hold an analyst/industry conference call

Biotechnology Analysts Van Buren & Duncan, along with Key Opinion Leader, Dr.William Lumry, discuss BioCryst's BCX7353 pipeline candidates which are in late-stage development for the prophylactic (oral capsule) and acute (oral liquid) treatment of HAE (Hereditary Angioedema) on an Analyst/Industry conference call to be held on April 18 at 1 pm.

TAK

Takeda Pharmaceutical

$17.88

-0.6 (-3.25%)

BCRX

BioCryst

$7.89

0.19 (2.47%)

KALV

KalVista

$24.82

-0.58 (-2.28%)

  • 18

    Apr

  • 24

    Apr

TAK Takeda Pharmaceutical
$17.88

-0.6 (-3.25%)

03/19/19
03/19/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Casa Systems (CASA) initiated with a Buy at DA Davidson. 2. Sterling Bancorp (SBT) initiated with an Overweight at Piper Jaffray. 3. Takeda Pharmaceutical (TAK) reinstated with a Buy at Goldman Sachs. 4. CyberArk (CYBR) initiated with an Outperform at FBN Securities. 5. Varex Imaging (VREX) initiated with an Outperform at Northland. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/19/19
GSCO
03/19/19
INITIATION
GSCO
Buy
Takeda Pharmaceutical reinstated with a Buy at Goldman Sachs
Goldman Sachs analyst Akinori Ueda reinstated Takeda with a Buy rating saying the Shire integration is the key catalyst to move shares higher.
BCRX BioCryst
$7.89

0.19 (2.47%)

03/06/19
PIPR
03/06/19
NO CHANGE
PIPR
Departure of Gottlieb brings some biopharma uncertainty, says Piper Jaffray
Piper Jaffray remains "largely bullish" on the biopharma sector but acknowledges a "new and unexpected" source of uncertainty now with the announced departure of FDA commissioner Scott Gottlieb, analysts led by Christopher Raymond tell investors in a research note. With a track record of favoring innovation and pushing for increased regulatory efficiency while also advocating for more competition, Dr. Gottlieb was about as "market friendly, patient focused and industry friendly as one could have hoped," Piper writes. The firm adds that while it has no reason to believe the next commissioner "will be quite as radical and potentially damaging to the industry," it does think investors would do well to watch the selection process very closely.
03/12/19
PIPR
03/12/19
NO CHANGE
PIPR
Biopharma stocks should be up sharply on Sharpless selection, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond said he expects biopharma stocks to be up sharply on news that former National Cancer Institute director Ned Sharpless will be named acting FDA commissioner. The biotech sector "experienced a swoon of sorts" since Scott Gottlieb announced his departure, but with the announcement of Gottlieb's favored choice as successor Raymond believes the FDA will remain "on its current industry-friendly and efficiency driven trajectory," the analyst tells investors.
04/02/19
LEHM
04/02/19
NO CHANGE
Target $8
LEHM
Equal Weight
BioCryst price target raised to $8 from $6 at Barclays
Barclays analyst Gena Wang raised her price target for BioCryst Pharmaceuticals to $8 from $6 following a deep dive ahead of the BCX7353 APeX-2 Phase 3 readout in Q2 for the prevention of hereditary angioedema attacks. The analyst believes APeX-2 is "well powered to allow for statistical significance" with only greater than 25-30% attack reduction. However, she continues to see some risk in the trial outcome and a high bar for future commercial uptake. Wang keeps an Equal Weight rating on BioCryst.
03/04/19
PIPR
03/04/19
NO CHANGE
Target $15
PIPR
Overweight
Piper Jaffray expects positive results from BioCryst's Phase III APeX-2 trial
Piper Jaffray analyst Tyler Van Buren "fully" expects positive results from BioCryst's Phase III APeX-2 trial next quarter and notes that the increased enrollment and improved powering is an encouraging development. Additionally, the analyst says that recent full presentation of the Phase II ZENITH-1 results for the 7353 oral liquid program continue to give him a high level of confidence in the future outcome of the Phase III trial. In addition to these two late stage programs, the company's pipeline is expanding rapidly with IV antiviral galidesivir, BCX9250 for FOP, and BCX9930 for complement-mediated diseases all entering the clinic this year, he adds. Van Buren reiterates an Overweight rating and $15 price target on the shares as he continues to have a high level of confidence in the $500M-plus potential of each the 7353 oral capsule and oral liquid assets and believes that the early-stage pipeline could generate significant additional value.
KALV KalVista
$24.82

-0.58 (-2.28%)

10/30/18
JEFF
10/30/18
INITIATION
Target $30
JEFF
Buy
KalVista initiated with a Buy at Jefferies
Jefferies analyst Maury Raycroft started KalVista with a Buy rating and $30 price target. The company's hereditary angioedema program has the potential to be the best-in-class oral HAE therapy in the acute setting with potentially some grey lines that may drive broader prophylactic use, Raycroft tells investors in a research note. He sees a buying opportunity at current share levels.
03/20/19
NEED
03/20/19
INITIATION
Target $35
NEED
Buy
KalVista initiated with a Buy at Needham
Needham analyst Serge Belanger initiated KalVista with a Buy rating and a price target of $35, saying the company is on track to become the "future leader of oral Kallikrein inhibitors" as it develops "novel treatments for hereditary angioedema and diabetic macular edema". The analyst notes that KalVista's KVD900 lead drug candidate has demonstrated a pharmacokinetics profile that "rivals injectables" and its tolerability profile is devoid of gastro-intestinal adverse events. Belanger expects the company's phase 2 results in late-2019 to confirm KVD900's best-in-class potential for the $1B acute HAE treatment market.
03/20/19
03/20/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Lyft (LYFT) initiated with a Buy at DA Davidson. 2. KalVista (KALV) initiated with a Buy at Needham. 3. Peabody Energy (BTU) initiated with an Outperform at Credit Suisse. 4. Fox (FOXA) initiated with a Buy at BofA/Merrill. 5. National General (NGHC) initiated with a Buy at Compass Point. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/15/18
STFL
10/15/18
INITIATION
Target $33
STFL
Buy
KalVista initiated with a Buy at Stifel
Stifel analyst Paul Matteis started KalVista Pharmaceuticals (KALV) with a Buy rating and $33 price target. The company's lead asset KVD900, an oral plasma kallikrein inhibitor, has a "realistic shot" at being a best-in-class acute therapy for hereditary angioedema, Matteis tells investors in a research note. He thinks clinical results from competitor BioCryst (BCRX) "corroborate the viability of the oral kallikrein inhibitor approach but simultaneously leave room for improvement."

TODAY'S FREE FLY STORIES

UBS

UBS

$13.16

0.07 (0.53%)

05:41
04/25/19
04/25
05:41
04/25/19
05:41
Hot Stocks
UBS sees higher recurring revenues in Global Wealth Management, Asset Management »

UBS provided the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 20

    May

  • 03

    Jun

FB

Facebook

$182.64

-1.13 (-0.61%)

05:38
04/25/19
04/25
05:38
04/25/19
05:38
Recommendations
Facebook price target raised to $215 from $195 at Baird »

Baird analyst Colin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 30

    May

  • 03

    Jun

UBS

UBS

$13.16

0.07 (0.53%)

05:37
04/25/19
04/25
05:37
04/25/19
05:37
Earnings
UBS reports Q1 EPS 30c, consensus 24c »

Reports Q1 book value per…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 20

    May

  • 03

    Jun

PYPL

PayPal

$107.18

0.27 (0.25%)

05:35
04/25/19
04/25
05:35
04/25/19
05:35
Recommendations
PayPal analyst commentary  »

PayPal price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

  • 14

    May

  • 22

    May

  • 03

    Jun

  • 11

    Jun

NOW

ServiceNow

$242.41

-1.085 (-0.45%)

05:32
04/25/19
04/25
05:32
04/25/19
05:32
Recommendations
ServiceNow analyst commentary  »

ServiceNow price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    May

CTXS

Citrix

$100.45

-0.4 (-0.40%)

05:29
04/25/19
04/25
05:29
04/25/19
05:29
Recommendations
Citrix analyst commentary  »

Citrix shares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALGN

Align Technology

$297.12

1.14 (0.39%)

05:27
04/25/19
04/25
05:27
04/25/19
05:27
Recommendations
Align Technology analyst commentary at Piper Jaffray »

Align Technology price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    May

  • 05

    Jun

MSFT

Microsoft

$125.00

-0.5 (-0.40%)

05:24
04/25/19
04/25
05:24
04/25/19
05:24
Recommendations
Microsoft analyst commentary  »

Jefferies boosts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 03

    Jun

  • 03

    Jun

  • 08

    Jun

  • 10

    Jun

  • 23

    Jun

  • 06

    Aug

IRBT

iRobot

$100.39

-30.03 (-23.03%)

05:21
04/25/19
04/25
05:21
04/25/19
05:21
Recommendations
iRobot analyst commentary at Piper Jaffray »

iRobot needs…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 24

    Jul

SWI

SolarWinds

$19.77

0.325 (1.67%)

05:17
04/25/19
04/25
05:17
04/25/19
05:17
Recommendations
SolarWinds analyst commentary at Jefferies »

SolarWinds price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    May

XLNX

Xilinx

$139.79

2.66 (1.94%)

05:15
04/25/19
04/25
05:15
04/25/19
05:15
Downgrade
Xilinx rating change  »

Xilinx downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    May

SIRI

Sirius XM

$5.71

-0.43 (-7.00%)

05:13
04/25/19
04/25
05:13
04/25/19
05:13
Upgrade
Sirius XM rating change  »

Sirius XM upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

APC

Anadarko

$71.41

7.29 (11.37%)

05:07
04/25/19
04/25
05:07
04/25/19
05:07
Downgrade
Anadarko rating change  »

Anadarko downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    May

  • 22

    May

CARO

Carolina Financial

$36.91

0.49 (1.35%)

05:06
04/25/19
04/25
05:06
04/25/19
05:06
Earnings
Carolina Financial reports Q1 operating EPS 65c, consensus 69c »

Reports Q1 book value per…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

JBAXY

Julius Baer

$0.00

(0.00%)

05:06
04/25/19
04/25
05:06
04/25/19
05:06
Downgrade
Julius Baer rating change  »

Julius Baer downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GD

General Dynamics

$180.67

-1.66 (-0.91%)

05:04
04/25/19
04/25
05:04
04/25/19
05:04
Upgrade
General Dynamics rating change at JPMorgan »

General Dynamics upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

  • 29

    May

NAVI

Navient

$12.96

0.51 (4.10%)

05:03
04/25/19
04/25
05:03
04/25/19
05:03
Upgrade
Navient rating change  »

Navient upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

PTC

PTC

$101.94

1.12 (1.11%)

05:02
04/25/19
04/25
05:02
04/25/19
05:02
Downgrade
PTC rating change  »

PTC downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DB

Deutsche Bank

$8.50

-0.04 (-0.47%)

04:59
04/25/19
04/25
04:59
04/25/19
04:59
Earnings
Deutsche Bank expects Q1 net income EUR 200M, revenue EUR 6.4B »

For the first quarter of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 29

    Apr

  • 03

    Jun

DB

Deutsche Bank

$8.50

-0.04 (-0.47%)

, CRZBY

Commerzbank

$0.00

(0.00%)

04:57
04/25/19
04/25
04:57
04/25/19
04:57
Hot Stocks
Deutsche Bank ends merger talks with Commerzbank, still reviewing alternatives »

Deutsche Bank (DB)…

DB

Deutsche Bank

$8.50

-0.04 (-0.47%)

CRZBY

Commerzbank

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 29

    Apr

  • 03

    Jun

CRZBY

Commerzbank

$0.00

(0.00%)

, DB

Deutsche Bank

$8.50

-0.04 (-0.47%)

04:55
04/25/19
04/25
04:55
04/25/19
04:55
Hot Stocks
Commerzbank announces end of merger talks with Deutsche Bank »

Commerzbank (CRZBY)…

CRZBY

Commerzbank

$0.00

(0.00%)

DB

Deutsche Bank

$8.50

-0.04 (-0.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 29

    Apr

  • 03

    Jun

04:55
04/25/19
04/25
04:55
04/25/19
04:55
General news
Breaking General news story  »

Week of 4/20 Jobless…

04:55
04/25/19
04/25
04:55
04/25/19
04:55
General news
Breaking General news story  »

Week of 4/19 EIA Natural…

04:55
04/25/19
04/25
04:55
04/25/19
04:55
General news
Breaking General news story  »

Week of 4/24 Fed Balance…

04:55
04/25/19
04/25
04:55
04/25/19
04:55
General news
Breaking General news story  »

3-Month Bill Announcement…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.